Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot safety and urinary porphyrin diagnostic study of oral Gliolan in colorectal cancer and healthy subjects
2023-508668-31-00Phase 2Authorised
- Sponsor
- photonamic GmbH & Co. KG
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 5-aminolevulinic acid in colorectal cancer (CRC) (2 cohorts), sponsored by photonamic GmbH & Co. KG. Primary endpoints: Number of adverse drug reactions and Discontinuations due to adverse drug reactions. Planned start Nov 2024; status: authorised.
02
Drugs
5-aminolevulinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2023-508668-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508668-31-00.